

University of Dundee

A SPE-HPLC-MS/MS method for the simultaneous determination of prioritised pharmaceuticals and EDCs with high environmental risk potential in freshwater

Li, Yuan; Taggart, Mark A.; McKenzie, Craig; Zhang, Zulin; Lu, Yonglong; Pap, Sabolc

Published in:
Journal of Environmental Sciences

DOI:
[10.1016/j.jes.2020.07.013](https://doi.org/10.1016/j.jes.2020.07.013)

Publication date:
2021

Licence:
CC BY-NC-ND

Document Version
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

Citation for published version (APA):

Li, Y., Taggart, M. A., McKenzie, C., Zhang, Z., Lu, Y., Pap, S., & Gibb, S. W. (2021). A SPE-HPLC-MS/MS method for the simultaneous determination of prioritised pharmaceuticals and EDCs with high environmental risk potential in freshwater. *Journal of Environmental Sciences*, 100, 18-27. <https://doi.org/10.1016/j.jes.2020.07.013>

General rights

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain.
- You may freely distribute the URL identifying the publication in the public portal.


Take down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

A SPE-HPLC-MS/MS method for the simultaneous determination of prioritised pharmaceuticals and EDCs with high environmental risk potential in freshwater

Yuan Li^{1,3}, Mark A. Taggart¹, Craig McKenzie², Zulin Zhang³, Yonglong Lu⁴, Sabolc Pap^{1,5}, Stuart Gibb¹

1. Environmental Research Institute, North Highland College, University of the Highlands and Islands, Castle Street, Thurso, Caithness, Scotland, KW14 7JD, UK. E-mail: Yuan.Li2@uhi.ac.uk
2. Forensic Drug Research Group, Centre for Anatomy and Human Identification, School of Science and Engineering, University of Dundee, Nethergate, Dundee, DD1 4HN, UK.
3. Environmental and Biochemical Sciences Group, James Hutton Institute, Craigiebuckler, Aberdeen, AB15 8QH, UK.
4. Research Centre for Eco-Environmental Sciences, Chinese Academy of Sciences, 18 Shuangqing Road, Haidian District, Beijing, 100085, China.
5. University of Novi Sad, Faculty of Technical Sciences, Department of Environmental Engineering and Occupational Safety and Health, University of Novi Sad, 21000 Novi Sad, Serbia.



Abstract: This work describes the development, optimisation and validation of an analytical method for the rapid determination of 17 priority pharmaceutical compounds and endocrine disrupting chemicals (EDCs). Rather than studying compounds from the same therapeutic class, the analyses aimed to determine target compounds with the highest risk potential with regard to Scotland, providing a tool for further monitoring in different water matrices. Prioritisation was based on a systematic environmental risk assessment approach, using consumption data; wastewater treatment removal efficiency; environmental occurrence; toxicological effects; and pre-existing regulatory indicators. This process highlighted 17 compounds across various therapeutic classes, which were then quantified, at environmentally relevant concentrations, by a single analytical methodology. Analytical determination was achieved using a single-step solid phase extraction (SPE) procedure followed by high-performance liquid chromatography with tandem mass spectrometry (HPLC-MS/MS). The fully optimised method performed well for the majority of target compounds, with recoveries >71% for 15 of 17 analytes. The limits of quantification for most target analytes (14 of 17) ranged from 0.07 ng·L⁻¹ to 1.88 ng·L⁻¹ in river waters. The utility of this method was then demonstrated using real water samples associated with a rural hospital/setting. Eight compounds were targeted and detected, with the highest levels found for the analgesic, paracetamol (at up to 105910 ng·L⁻¹ in the hospital discharge). This method offers a robust tool to monitor high priority pharmaceutical and EDC levels in various aqueous sample matrices.

Keywords:

Pharmaceuticals
Prioritisation
risk assessment
trace level determination
water quality

***Corresponding author.** E-mail: Yuan.Li2@uhi.ac.uk (Yuan Li, Environmental Research Institute, Castle Street, Thurso, Scotland, UK, KW14 7JD)

52 **Introduction**

53 The discovery and use of pharmaceuticals is one of society's greatest advances, leading
54 to increased human lifespan and promoting improved health (Johansson, 1998). An
55 unintended consequence of the widespread use of human pharmaceuticals has however
56 been their inadvertent and now ubiquitous introduction into the aquatic environment. This
57 commonly occurs as a result of the excretion (in urine/faeces) of unmetabolised parent
58 compounds and the improper disposal of unused or expired medicinal products – both of
59 which pass into sewage networks (where these are present) and then remain in treated
60 wastewater discharges (Cahill et al., 2004; Charuaud et al., 2019; Fekadu et al., 2019;
61 Kallenborn et al., 2018). Numerous studies have now demonstrated the incomplete
62 removal of pharmaceuticals by sewage treatment systems, with as much as 80% of the
63 total load of any particular pharmaceutical entering the treatment network ultimately
64 being released into the receiving aquatic environment (Botero-Coy et al., 2018; Östman
65 et al., 2018; Ruan et al., 201; Yuan et al., 2014).

66 The potential effects of pharmaceutical pollution may include the promotion of multi-
67 drug resistant bacterial strains and/or deleterious acute or chronic ecotoxicological
68 impacts on non-target organisms (Brodin et al., 2013; Hernando-Amado et al., 2019;
69 Kumar et al., 2019). For example, fluoxetine has been shown to cause reproductive delay
70 in leopard frogs (Foster et al., 2010; Fursdon et al., 2019; Hellström et al., 2016), while
71 ciprofloxacin can cause genotoxic effects in plankton and algae (Carusso et al., 2018)
72 (Dionísio et al., 2020). Further, certain pharmaceuticals are also endocrine disrupting
73 chemicals (EDCs), and have been shown to exert significant reproductive effects even at
74 trace environmental levels. For example, 17 α -ethinylestradiol (a synthetic hormone
75 commonly used in birth control pills) has been extensively studied in fish and shown to
76 cause delays in embryonic development (Almeida et al., 2020; Huff et al., 2018),
77 vitellogenin induction (Zhang et al., 2019; Zhou et al., 2019), intersex development
78 (Jackson et al., 2019; Ujhegyi and Bókonyi, 2020) and thus reduced reproductive success
79 (Colman et al., 2009; Roy et al., 2018).

80 The ongoing discharge of pharmaceuticals and EDCs into the wider environment
81 potentially poses a risk to human health and as such there remains a need to evaluate their
82 presence, fate and behaviour in various environmental compartments. This requires the
83 development of robust, sensitive and accurate analytical methods for the simultaneous
84 extraction, detection and quantification of these chemicals at low, environmentally

85 relevant levels. The most common analytical approach to determine pharmaceuticals and
86 EDC levels in aqueous samples first involves a pre-concentration step (i.e., using solid
87 phase extraction; SPE), and then the use of liquid chromatography with mass
88 spectrometric detection (LC-MS) (Buchberger, 2011; Hong et al., 2019; Peng et al., 2019).
89 However, many methods focus on compounds that are simply most commonly found (i.e.,
90 in water), or, that belong to specific drug classes, i.e., antibiotics (Gurke et al., 2015a,
91 2015b; Rossmann et al., 2014; Scheurer et al., 2009). As such, there remains a need to
92 develop techniques specifically focussed on those substances thought to pose the greatest
93 risk potential within the aquatic environment. Such methods can be informed by existing
94 prioritisation systems such as those which have led to the creation of “Watch Lists” within
95 the EU Water Framework Directive (WFD, EU) and the UK’s Chemical Investigation
96 Program (CIP, UK) (European commission, 2015; UKWIR, 2015). Such regulatory
97 indicators act to highlight those compounds thought to be of most concern and/or
98 requiring more detailed research.

99 In this study, we describe the development of an SPE protocol combined with subsequent
100 HPLC-MS/MS (high performance liquid chromatography with tandem mass
101 spectrometry) analysis for the routine determination of selected pharmaceuticals and
102 EDCs (first prioritised based on their high environmental risk potential). The work
103 presented involves: (1) prioritisation of compounds across a range of therapeutic classes
104 – all with significant potential to pose risks to the aquatic environment; (2) development
105 of a rapid and sensitive method to measure these compounds at environmentally relevant
106 concentrations ($\text{ng}\cdot\text{L}^{-1}$); (3) an evaluation of possible matrix effects using different water
107 types; and (4) application of the methodology to real samples collected from a range of
108 sites as part of a hospital discharge focused monitoring study.

109 **1. Methodologies and chemicals**

110 **1.1 Chemicals and reagents**

111 All prioritised compound standards were of the highest purity available (>98%) and
112 supplied by Sigma-Aldrich (UK). Isotopically labelled internal standards were purchased
113 from Qmx. Both individual compound stock standards and isotopically labelled internal
114 standards (ILIS) were prepared in methanol, except for ciprofloxacin, which was
115 dissolved in methanol containing 1 μM NaOH to enhance solubility. Mixed compound
116 standards and calibration standards were prepared using appropriate dilutions of

individual stock solutions, in 50:50 v/v methanol:Milli-Q[®] water. All solutions were stored in amber glass vials at –20°C in the dark.

HPLC-grade acetonitrile, ethyl acetate, acetone and methanol were provided by VWR Chemicals (Poole, England). Formic acid, acetic acid, ammonium acetate and ammonium hydroxide were all analytical grade and supplied by Sigma–Aldrich. Oasis HLB 6cc (200 mg) and Oasis HLB Prime 6cc (200 mg) SPE cartridges were obtained from Waters Corporation (Milford, MA, USA).

1.2 Instrumentation

The quantification of target analytes was performed using a HPLC-MS/MS system, consisting of an Agilent 1100 HPLC with a CTC PAL auto-sampler coupled to a Micromass Quattro Ultima Platinum mass spectrometer (Manchester, UK) equipped with an electrospray ionisation source (ESI). Ions were acquired in multiple reaction monitoring (MRM) mode. Precursor ions for each compound were determined by direct infusion of individual compound standards whilst in full-scan mode (at m/z 50-1000). During infusion the optimum cone voltage (CV) to achieve maximum signal response for each ion was selected. Product ion scanning was then performed to obtain product ions, and collision energy (CE) was optimised for each individual analyte. The highest intensity characteristic precursor to product ion MRM transition was used for quantification (quantifier), while a second was used for confirmation (qualifier). To sustain an adequate signal response for every compound, analytes were measured within optimised time windows. Data acquisition and analysis were carried out using MassLynx 4.1 software (Micromass, Manchester, UK).

1.3 Sample preparation

SPE was employed for sample enrichment and clean-up, and several stationary phases were tested under a range of elution conditions to optimise compound recovery (see [Fig. S1 for schematic of the process](#)). All SPE experiments were conducted in triplicate, using 20 mL of Milli-Q water spiked to a starting concentration of $10\text{ }\mu\text{g}\cdot\text{L}^{-1}$ for each analyte (ultimately $500\text{ }\mu\text{g}\cdot\text{L}^{-1}$ in final extract/following the SPE process, assuming 100% recovery). For the final protocol, SPE cartridges were preconditioned with methanol (6 mL) and then Milli-Q water (6 mL), both at a flow rate of $1\text{ mL}\cdot\text{min}^{-1}$. 20 mL spiked water samples were passed through the cartridges at a flow rate of $1\text{ mL}\cdot\text{min}^{-1}$ and then cartridges were rinsed with Milli-Q water once (1 mL). Cartridges were then dried under

vacuum for >30 min to remove excess water. Then, the analytes were eluted with two consecutive 6 mL elution's using methanol (MEOH), or, acetone (ACE) and ethyl acetate (EAC) at 50:50 v/v (depending on desired recoveries for certain compounds), at 1 mL·min⁻¹. The eluates were then evaporated under a gentle stream of high purity nitrogen at 40°C until they were almost dry, then reconstituted with 0.4 mL of 50:50 v/v MEOH:Milli-Q. Absolute recoveries were determined compared to quality-control (QC) standards of 500 µg·L⁻¹.

1.4 Method quantification

Compound selectivity was verified by measuring two MRM transitions per analyte. Calibration linearity was studied by analysing standards in triplicate at nine concentrations in the range from 2 to 500 µg·L⁻¹. Satisfactory linearity using weighed (1/x) least squares regression was assumed when the correlation coefficient (R^2) was > 0.99. Method accuracy and precision (expressed as recovery and repeatability, using relative standard deviation) were studied with recovery experiments (using Milli-Q water spiked with analytes). Instrumental limits of detection (LOD) for each compound were determined as the minimum detectable amount of analyte giving a signal-to-noise (S/N) ratio of 3 (using the quantification transition).

For the investigation regarding matrix effects, a known amount of analyte (10 µg·L⁻¹) and ILIS (1 µg·L⁻¹) was added to tap water and river water (filtered and unfiltered). Taking into account an enrichment factor of 50 (whereby 20 mL of water sample was reconstituted into 0.4 mL for analysis following SPE), quality-control (QC) standards of 500 µg·L⁻¹ (for the analytes) and 50 µg·L⁻¹ (for the ILIS) were then used for quantification.

1.5 Application to real samples

A range of water samples were collected from sites associated with/in the vicinity of a rural UK hospital (in Caithness, Scotland). These were (1) the local potable untreated surface water source, (2) the hospital water inflow, (3) the hospital combined wastewater effluent discharge, (4) the combined local municipal WWTP influent and (5) the combined effluent from the same municipal WWTP (for Wick town, Caithness). A subset of 8 target compounds were monitored over 4 weeks at these sites. Water samples (2 L) were collected in amber glass bottles and 1 L was filtered through 0.7 µm glass microfiber filters (47 mm, MF300, Fisher Scientific, UK). Filtrates were spiked with 0.25 mL of ILIS mixed standard working solution (at 100 µg·L⁻¹; equivalent to a 25 ng·L⁻¹

concentration in 1 L of sample). SPE cartridges were preconditioned with MEOH and Milli-Q water, then 1L water samples were passed through the cartridges at a flow rate of 1 mL·min⁻¹. The SPE extract was eluted with 2×6 mL MEOH and reconstituted with 0.5 mL of 50:50 v/v MEOH:Milli-Q, leading to an enrichment factor of 2,000 and a final concentration of 100 µg·L⁻¹ ILIS in the analysed sample. Quantification was made using external QC standards and calibration standards, with recovery assessed based on relative responses. To ensure the precision and accuracy of the data required, all targeted compounds in real water analysis have been assigned with their own ILIS standards to correct possible quantification errors. All samples were stored at 4°C in the dark until SPE extraction, which was performed within 48 hr of sample collection.

2. Results and Discussion

2.1 Prioritisation of target compounds

As there are > 3,000 pharmaceuticals registered for use in the European Union (EU), it is necessary to prioritise these whilst accounting for risk (Boxall et al., 2012). Many prioritisation schemes have been proposed in recent years, commonly based on consumption data, environmental occurrence and/or toxicological effects (Kötke et al., 2019; Li et al., 2020; Mansour et al., 2016; Pereira et al., 2016; Roos et al., 2012). However, many field monitoring studies still focus on compounds that are most commonly found in water (López-Serna et al., 2011; Rossmann et al., 2014) – many of which may (or may not) be likely to elicit toxicological effects.

Here, a systematic prioritisation approach was first used to identify compounds that may pose the greatest risk in the aquatic environment. For the evaluation of the environmental risk of pharmaceuticals and EDCs, it is difficult to estimate if adverse effects (both acute and chronic toxicity as well as other potentially more subtle biological and behavioural effects) on non-target organisms occur at environmentally relevant concentrations. In this study, a risk score was used as a primary prioritisation parameter to characterize substances that pose potential ecological risks to the aqueous environment by comparing their environmental occurrence with their known toxicologically relevant concentrations. The risk score - hazard quotient (HQ) value was calculated as the ratio between measured environmental concentration (MEC) and the predicted no effect concentration (PNEC; i.e., the environmental level at which no adverse effect on relevant non-target

organisms/ecosystem function is expected) (Booth et al., 2020). When the $HQ \geq 1$, a high risk of adverse effects is expected (De Souza et al., 2009; Ccancapa et al., 2016).

Although there are (as yet) no legally binding discharge limits set in the EU for pharmaceuticals and EDCs, multiple compounds have been highlighted as ‘priority substances’ for further investigation by EU and UK regulatory frameworks, i.e., through ‘Watch Lists’ created as part of the EU Water Framework Directive (WFD) and the priority lists created through the UK’s Chemical Investigation Programme (CIP) (European commission, 2018; UKWIR, 2019). These result in increased monitoring and research and may ultimately lead to statutory discharge limits for certain compounds (Brack et al., 2017; Miarov et al., 2020; Nijsingh et al., 2019; Petrie et al., 2015; Voulvoulis et al., 2017). As such, these regulatory indicators have also been taken into account here.




Fig.1. Decision tree of compound prioritisation

Here, the first step in our prioritisation process was to consider prescription rates within Scotland. As shown in Fig.1, pharmaceuticals were first grouped by therapeutic class, and within each class, compounds prescribed >100,000 times per year (ISD Scotland, 2016) were highlighted. Substances prescribed below this value were only highlighted if they had been listed as existing priorities within the EU’s WFD Watch List(s) and/or the UK’s CIP Programme. Analytes highlighted were then evaluated further by considering WWTP removal efficiency, reported environmental concentrations (in water) and toxicological risk. Combining the reviewed range of pharmaceutical and EDC monitoring data (MEC) and their PNEC values, the risk scores were calculated to characterize

235 substances that have pose potential adverse effects to the aqueous environment at current
236 detection levels. All preliminarily prioritised substances were then considered in terms of
237 their physico-chemical properties – and where these had very similar molecular structures
238 (which may then result in similar environmental fate), a single substance was selected as
239 representative of a certain group.

240 The prioritisation selection criteria applied here were, in summary: a) prescription
241 statistics ([ISD Scotland, 2016](#)); b) legislative indicators, i.e., WFD ‘Watch List’ and/or
242 UK CIP listed; c) removal efficiency in WWTP; d) environmental occurrence in water;
243 e) biological toxic effects (informed by HQ calculated with PNEC and MEC); and f)
244 physico-chemical properties. **Table 1** shows a summary regarding the prioritised list of
245 compounds targeted in this study ([Li et al., 2019](#)).

Table 1. Prioritised compounds in this study and the criteria and data used

Class	Compounds	Use statistics ¹ (items)	Legislative indicator	WWTP removal efficiency (%)	Environmental occurrence (ng·L ⁻¹)	PNEC ² (ng·L ⁻¹)	HQ ³ (>1?)	Log K _{ow}	pK _a
Antibiotic (anti-infective)	Trimethoprim	487128	No	0-50	10-28000	500	56	0.9	7.1
Antibiotic (macrolide)	Clarithromycin	268489	EU ^{a,b} +UK ⁴	0-24	3.5-621	250	2.5	3.2	8.9
Antibiotic (Fluoroquinolone)	Ciprofloxacin	99441	EU ^b +UK	45-78	6–2500	100	25	0.3-0.7	5.9; 8.9
Antimicrobial	Triclosan	10-1000 t/yr ⁵	UK	45-89	3.9-434	50	8.68	4.2-4.8	7.9
Analgesic	Paracetamol	5482031	No	0-90	160-65000	1000	65	0.5-0.9	9.5
NSAID ⁶	Ibuprofen	915788	UK	72-90	44–990000	1650	600	4.0	4.9
NSAID	Diclofenac	595709	EU ^a +UK	9-60	10–510000	3310	154	4.5	4.2
SSRI ⁷	Fluoxetine	816346	UK	3-60	2.1-2000	110	18.2	1.2	10.1
Antiepileptic	Carbamazepine	223601	UK	0-53	290–4596	420	10.9	2.47	13.9
Metabolite	Carbamazepine- 10-11-epoxide	N/A ⁸	UK	N/A	8-2100	N/A	N/A	1.26	13.9
β-blocker	Propranolol	557628	UK	34-80	108-1130	244	4.63	0.78	9.5
Blood lipid regulator	Atorvastatin	1637000	UK	40-80	10-210	86	2.44	6.36	4.46
Anti-diabetic	Metformin	1140162	UK	0-85	100-47000	13450	3.49	1.3	12.4
Steroid hormone (Natural)	Estrone (E1)	N/A	EU ^{ab} +UK	0-61	1.8-60	6	10	2.45-3.43	10.5
Steroid hormone (Natural)	17β-Estradiol (E2)	N/A	EU ^{ab} +UK	0-87	0.72-51	2	25.5	3.94-4.01	10.7
Steroid hormone (Synthetic)	17α-ethynyl estradiol (EE2)	298045	EU ^{ab} +UK	0-85	0.36-4.3	0.35	12.3	3.67–4.15	10.4
Steroid hormone (Natural) ⁹	Estriol (E3)	N/A	No	0-90	0.11-18	60	0.3	2.55-2.81	10.4

1. Prescription statistics for Scotland 2014-15 ([ISD Scotland, 2016](#)); 2. Predicted no-effect concentration (PNEC); 3. Hazard quotient (HQ) incorporating MEC with PNEC; 4. EU a. Commission Implementing Decision 2015/495 ([European commission, 2015](#)); b. 2018/840 ([European commission, 2018](#)); UK, Chemical Investigation Programme ([UKWIR, 2019](#)); 5. Triclosan usage in EU per year; 6. Nonsteroidal anti-inflammatory drugs (NSAIDs); 7. Selective serotonin reuptake inhibitors (SSRIs); 8. N/A, not applicable/available. 9. References used for the prioritisation data are listed in [Table. S1 \(supporting information\)](#).

Ultimately, 17 compounds were identified as priority substances here, belonging to a wide range of compound classes (11), i.e., antibiotics, antimicrobials, analgesics, non-steroidal anti-inflammatory drugs, psychoactive drugs, β -blockers, blood lipid regulators, antidiabetics, anti-ulcer agents and estrogens (as well as associated metabolites). Fifteen compounds were associated with high potential risk ($HQ > 1$) within the aqueous environment, including ibuprofen, diclofenac, paracetamol, trimethoprim, E2, ciprofloxacin, fluoxetine, EE2, carbamazepine, E1, propranolol, metformin, clarithromycin, atorvastatin and triclosan (in HQ value order from high to low). This largely aligns with key legislative indicators (given these were also one of our criteria), with the only pharmaceutical compounds in addition to CIP/WFD indicators being trimethoprim and paracetamol. These two compounds have been highlighted as their current occurrence levels outstrip its known toxicologically relevant concentrations (PNEC) as shown in **Table 1**, the high HQ scores of trimethoprim (56) and paracetamol (65) indicated that the adverse effects on non-target organisms may occur in the aquatic environment. Trimethoprim is the second most commonly prescribed antibiotic in Scotland, and reports show that up to 80% of this is excreted unmetabolised by the human body (De Liguoro et al., 2012; Kasprzyk-Hordern et al., 2009). It has been found to be resistant to the biological wastewater treatment (Lindberg et al. 2006), one of the most frequently occurring antibiotics found in UK wastewaters, being detected in 65% of effluent samples with a maximum concentration of 1,300 $\text{ng}\cdot\text{L}^{-1}$ (Ashton, Hilton & Thomas 2004). Similarly, paracetamol is one of the most commonly prescribed drugs globally, due to its antipyretic and analgesic properties. Even though the reported removal efficiencies in WWTPs are relatively high (up to 90%), it is often found at high levels in the aquatic environment (e.g., maximum 10,000 $\text{ng}\cdot\text{L}^{-1}$ in US natural waters and at 65,000 $\text{ng}\cdot\text{L}^{-1}$ in the River Tyne, UK) (Kolpin et al., 2002; Roberts and Thomas, 2006). Such high levels of paracetamol continuously introduced into the aquatic environment have been found to cause negative ecological effects in various wild organisms (Nunes et al., 2014), the high HQ scores of these compounds in this study reinforced the necessity of further investigation of such pollutants.

UK CIP (UKWIR, 2019) identified a wide range of substances that may pose a significant risk to the environment in the UK. Following the prioritisation procedure used here, fourteen compounds on CIP were prioritised for investigation. At EU level, priority substances were first introduced under the WFD Commission Implementing Decision (EU) 2015/495, which listed ten watch list substances, and required this list to be updated every two years according to Commission Implementing Decision (EU) 2008/105 (European commission, 2008).

Accordingly, diclofenac was originally prioritised in the first WFD watch list (European commission, 2015) and monitored intensively. On the basis of sufficient high-quality monitoring data available for this compound, diclofenac has since been removed from the watch list in June 2018 (European commission, 2018). Meanwhile, the antibiotic ciprofloxacin has been added due to its potential to drive antimicrobial resistance in the environment. Macrolide antibiotics (clarithromycin, erythromycin and azithromycin) have been retained in the watch list, while, clarithromycin, the highest prescribed macrolide, was chosen as the representative compound, based on the fact that these substances have similar molecular structures and physico-chemical properties.

As well as ‘parent’ pharmaceutical compounds, one of the 17 compounds listed here is a metabolite. While most studies tend to focus on primary pharmaceuticals, there is now increased recognition that excreted metabolites may also pose risks in the environment (Roberts and Thomas, 2006). Carbamazepine, one of the most prominent anti-epileptic drugs with annual worldwide usage of 1,014 tons and 223,601 prescription in Scotland has been targeted in this study due to the poor removal in WWTP, high detection levels and potential risks in the environment (ISD Scotland, 2016; Radjenović, Petrović & Barceló 2009). As well as ‘parent’ pharmaceutical compound, the metabolite of carbamazepine, carbamazepine-10-11-epoxide has been found to be biologically active and shows similar or higher toxicity relative to its parent compound (Calisto and Esteves, 2009; Miao and Metcalfe, 2003). Therefore, carbamazepine-10-11-epoxide has been included as a representative metabolite. Moreover, there are several potent natural estrogens of concern (estrone (E1), 17 β -estradiol (E2) and estriol (E3)), which are not dissimilar to the synthetic xenoestrogen - 17 α -ethynyl estradiol (EE2) which has been of concern for many years (Burkhardt-Holm, 2010; Czarny et al., 2019; Qin et al., 2020; Yu et al., 2019). Three of these four EDCs (E1, E2 and EE2) have also been highlighted by both the EU’s WFD Watch List schemes and the UK’s CIP system. As estriol (E3) poses ecotoxicological effects similar to E1, E2, and EE2, this estrogen has also been targeted for investigation here.
















2.2 Detection method development

2.2.1 HPLC separation and MS/MS optimisation











To optimise compound separation and sensitivity, methanol and acetonitrile along with different buffers (ammonium acetate, ammonium hydroxide, formic acid and acetic acid at

various concentrations) were tested as mobile phases. MS parameters were optimised to attain maximum sensitivity and selectivity. Of the 17 substances, 10 showed a higher response using the protonated $[M+H]^+$ ions and positive ion (PI) mode while 7 were better using negative mode (detecting the deprotonated $[M-H]^-$ ions). For both modes, several HPLC columns and various operational parameters/gradient designs (i.e., different flow rates and slopes) were tested in order to optimise peak separation, signal response and minimise run time. Good peak shape and sensitivity were achieved in PI mode using a reverse-phase Waters XBridge BEH C18 column (2.1 mm I.D. x 100 mm, 2.5 μ m) with 0.1% formic acid as the aqueous phase and acetonitrile at 45°C. For the 7 NI compounds, sufficient separation was obtained using 0.025% ammonium hydroxide (in water) and acetonitrile and a Phenomenex Kinetex EVO C18 column (3.0 mm I.D x 100 mm, 2.6 μ m) at 25°C. The optimised gradient elution programs used are shown in [Table S2 \(Supporting Information\)](#) alongside representative chromatograms for pure standard mixtures monitored in both modes ([Fig. S2](#)). Optimised mass spectrometry parameters, precursor and product ions, retention times (RT) and instrumental LODs in both PI and NI modes are summarised in [Table 2 and 3](#), respectively.

326 **Table 2.** Mass spectrometry parameters for target compounds analysed in positive ionisation (PI)

Compound	Mol. Weight (g·mol ⁻¹)	Precursor ion	CV ¹ (V)	Product ions	CE ² (eV)	RT ³ (min)	Corresponding ILIS	Molecular structure	LODs ⁴ (µg·L ⁻¹)
Metformin	129	130	45	60 71	8 10	1.22	Paracetamol -D4		0.072
Paracetamol	151	152	45	110 93	10 16	3.78	Paracetamol -D4		0.213
Paracetamol-D4	155	156	45	114 97	10 16	3.81	-		-
Trimethoprim	290	291	60	230 261	20 20	7.69	Trimethoprim -D9		0.049
Trimethoprim-D9	299	300	60	264 234	20 20	7.64	-		-
Ciprofloxacin	331	332	55	288 245	14 20	7.99	Trimethoprim -D9		0.107
Carbamazepine-10-11-epoxide	252	253	40	236 180	6 16	11.29	Carbamazepine -D10		0.054
Carbamazepine-D10	246	247	60	204 201	14 16	13.34	-		-
Propranolol	259	260	50	116 183	14 14	11.81	Carbamazepine -D10		0.143
Carbamazepine	236	237	60	194 192	14 16	13.39	Carbamazepine -D10		0.057
Clarithromycin	748	749	60	158 590	26 16	15.11	Roxithromycin		0.039
Roxithromycin	837	838	60	679 158	26 16	15.16	-		-
Fluoxetine	309	310	35	44 148	8 6	15.42	FLX-D5		0.052
Fluoxetine-D5	314	315	35	44 153	8 6	15.37	-		-
Atorvastatin	559	560	50	440 466	18 14	19.71	Fluoxetine-D5		0.059

328 **Table 3.** Mass spectrometric parameters for target compounds analysed in negative ionisation (NI)

Compound	Mol. Weight (g·mol ⁻¹)	Precursor ion	CV ¹ (V)	Product ion	CE ² (eV)	RT ³ (min)	Corresponding ILIS	Molecular structure	LODs ⁴ (µg·L ⁻¹)
Ibuprofen	206	205	35	161	4	2.21	Diclofenac-D4		0.272
Diclofenac	296	294	35	250 214	8 18	4.14	Diclofenac-D4		0.428
Diclofenac-D4	300	298	35	254 217	8 18	4.15	-		-
Estriol	288	287	115	171 145	30 30	5.64	E1-D2		2.177
Estrone-D2	272	271	105	145 159	28 28	11.49	-		-
17β-Estradiol	272	271	125	145 183	28 30	10.46	E1-D2		0.771
17α-ethynylestradiol	296	295	125	145 159	28 30	11.17	E1-D2		1.082
Estrone	270	269	125	145 159	28 28	11.44	E1-D2		0.376
Triclosan	289	289 287	35	35 35	4 4	13.72	Triclosan-D3		0.891
Triclosan-D3	292	290	35	35 37	4 4	13.72	-		-

329 1. CV - cone voltage; 2. CE - collision energy; 3. RT - retention time; 4. LOD - limit of detection.

330 All compounds had two abundant product ions, except ibuprofen, for which only one was
 331 monitored due to poor fragmentation. Transitions identified here are in agreement with those
 332 from other studies (Löffler and Ternes, 2003; Jelić et al., 2009; Ferrer et al., 2010; Golet et al.,
 333 2001).

334 2.2.2 Optimisation of Solid Phase Extraction (SPE) procedure

A number of SPE protocols (different cartridges, elution solvents, pH conditions, etc.) were evaluated for pharmaceutical and EDC recovery. The choice of SPE stationary phase can play a crucial role in enhancing recovery of analytes and SPE selection is frequently based on the physico-chemical properties of target compounds. Here, the lipophilic-hydrophilic-balanced, reverse-phase polymeric sorbent Oasis HLB cartridge was used to accommodate the wide range of physico-chemical characteristics exhibited by the prioritised pharmaceuticals and EDCs (with pK_a ranging from 4.2 to 13.9, and Log K_{ow} from 0.28-6.36). This cartridge has also been shown to be less susceptible to matrix effects than other media (Gorga et al., 2013; Van De Steene et al., 2006; Vazquez-Roig et al., 2010). Two HLB cartridges (Oasis HLB and Oasis HLB Prime) were evaluated using methanol and acetone:ethyl acetate at 50:50 v/v as solvents. To study any pH related recovery effects, different solution pH values were tested (i.e., no pH adjustment or pH = 2). The average absolute recoveries (and relative standard deviations (SD)) for each target compound are shown in Table 4.

To evaluate possible quantification errors introduced by analyte loss during sample processing and fluctuations in instrument sensitivity, $1 \mu\text{g}\cdot\text{L}^{-1}$ of ILIS was added as a surrogate to samples prior to extraction ($\text{ILIS} = 50 \mu\text{g}\cdot\text{L}^{-1}$ post-SPE, assuming 100% recovery). The ILIS compounds applied in this study were selected based on the following criteria: (i) a ^2H -isotope or a ^{13}C labelled isotope compound - which shared the same (or very similar) physico-chemical properties to the analyte; (ii) with a chromatographic retention time close to that of the analyte; (iii) and similar SPE recovery and ionisation response to the analyte. Given the large number of compounds targeted here it was unfeasible to correct each analyte with its own individual ILIS, hence, ILIS analogues were used for certain groups (i.e., E1-D2 for the four estrogens) on the basis of compound similarity, retention time and recovery. Relative recoveries (calculated using the recovery data for the ILIS compounds), and the ILIS compounds used, are presented in Table 5.

Table 4. Absolute mean SPE recoveries of prioritised pharmaceuticals and EDCs using different SPE protocols

No.	Recoveries % and (±%RSD)		Analytes detected in -ve mode							Analytes detected in +ve mode										No. >75% and <125%
			IBU	DCF	E3	E2	EE2	E1	TCS	MET	PARA	CFX	TMP	CBZE	PPL	CBZ	CTM	FLX	ATV	
1	MEOH	HLB	35 (±17)	67 (±4)	38 (±10)	36 (±6)	41 (±5)	44 (±6)	34 (±2)	45 (±16)	90 (±6)	2 (±0)	38 (±1)	59 (±1)	39 (±3)	51 (±1)	49 (±6)	35 (±0)	10 (±1)	1
		HLB Prime	71 (±10)	83 (±3)	65 (±4)	75 (±4)	87 (±0)	56 (±10)	67 (±11)	74 (±6)	93 (±2)	2 (±0)	56 (±1)	90 (±1)	68 (±4)	83 (±2)	45 (±1)	45 (±5)	12 (±2)	6
2	ACE:EAC	HLB	56 (±5)	77 (±2)	37 (±10)	33 (±14)	40 (±13)	49 (±3)	59 (±2)	11 (±12)	90 (±4)	3 (±3)	38 (±2)	65 (±7)	6 (±1)	52 (±3)	26 (±5)	1 (±0)	11 (±3)	2
		HLB Prime	90 (±6)	91 (±2)	97 (±3)	111 (±9)	101 (±3)	107 (±4)	98 (±8)	11 (±3)	99 (±2)	1 (±0)	42 (±1)	98 (±0)	28 (±6)	102 (±4)	26 (±7)	0 (±0)	27 (±5)	10
3	pH 2 MEOH	HLB	29 (±2)	30 (±3)	29 (±72)	30 (±1)	38 (±1)	53 (±0)	53 (±3)	3 (±1)	72 (±2)	195 (±21)	34 (±1)	5 (±1)	47 (±1)	49 (±0)	26 (±3)	45 (±0)	10 (±4)	0
		HLB Prime	43 (±7)	46 (±10)	63 (±7)	66 (±8)	63 (±3)	104 (±7)	77 (±4)	3 (±0)	96 (±4)	145 (±6)	74 (±9)	22 (±2)	81 (±1)	85 (±0)	27 (±6)	84 (±5)	11 (±4)	6
4	pH 2 ACE:EAC	HLB	57 (±1)	36 (±1)	27 (±3)	29 (±4)	37 (±5)	49 (±0)	62 (±10)	2 (±0)	81 (±1)	36 (±11)	42 (±8)	20 (±1)	40 (±8)	54 (±6)	9 (±1)	32 (±2)	6 (±1)	1
		HLB Prime	58 (±6)	63 (±0)	73 (±1)	77 (±4)	75 (±3)	121 (±19)	91 (±8)	1 (±1)	88 (±6)	144 (±2)	56 (±0)	25 (±1)	91 (±4)	94 (±11)	14 (±1)	46 (±1)	14 (±3)	7

Table 5. Mean SPE recoveries of prioritised pharmaceuticals and EDCs calculated using the ILIS recovery data to correct responses

No	Recoveries % and (±%RSD)		Analytes detected in -ve mode							Analytes detected in +ve mode										No. >75% and <125%
			IBU	DCF	E3	E2	EE2	E1	TCS	MET	PARA	CFX	TMP	CBZE	PPL	CBZ	CTM	FLX	ATV	
	Applied ILIS		DCF-D4		E1-D2			TCS-D3	TMP-D9				CBZ-D10			RTM	FLX-D5			
1	MEOH	HLB	48 (±21)	77 (±3)	66 (±13)	60 (±5)	56 (±4)	88 (±2)	101 (±6)	49 (±5)	64 (±1)	1 (±0)	51 (±6)	94 (±10)	60 (±2)	85 (±4)	129 (±4)	45 (±1)	39 (±3)	5
		HLB Prime	64 (±6)	92 (±3)	112 (±8)	103 (±6)	96 (±5)	97 (±3)	92 (±4)	102 (±26)	210 (±19)	4 (±1)	117 (±3)	95 (±1)	63 (±0)	88 (±1)	126 (±4)	85 (±1)	113 (±5)	12
2	ACE:EAC	HLB	69 (±5)	77 (±1)	77 (±4)	91 (±10)	104 (±7)	91 (±10)	97 (±1)	3 (±0)	85 (±18)	3 (±2)	45 (±9)	126 (±7)	3 (±0)	89 (±0)	127 (±11)	83 (±24)	80 (±17)	10
		HLB Prime	80 (±2)	94 (±1)	96 (±6)	99 (±4)	93 (±3)	96 (±3)	99 (±3)	31 (±7)	227 (±6)	2 (±1)	113 (±2)	99 (±1)	29 (±7)	90 (±0)	135 (±16)	82 (±5)	123 (±7)	12
3	pH 2 MEOH	HLB	56 (±3)	77 (±0)	46 (±2)	57 (±2)	83 (±11)	71 (±4)	93 (±2)	1 (±0)	40 (±2)	62 (±4)	95 (±2)	3 (±1)	77 (±8)	80 (±3)	104 (±4)	95 (±1)	9 (±0)	8
		HLB Prime	147 (±28)	101 (±2)	66 (±6)	83 (±4)	92 (±1)	103 (±5)	110 (±1)	4 (±2)	126 (±18)	221 (±5)	134 (±6)	33 (±3)	116 (±3)	120 (±3)	133 (±2)	95 (±0)	67 (±16)	8
4	pH 2 ACE:EAC	HLB	79 (±6)	80 (±1)	64 (±7)	74 (±9)	100 (±3)	67 (±17)	103 (±4)	1 (±0)	63 (±4)	61 (±9)	92 (±7)	21 (±0)	79 (±1)	86 (±1)	111 (±0)	88 (±2)	10 (±1)	9
		HLB Prime	161 (±13)	101 (±1)	98 (±25)	117 (±46)	116 (±36)	99 (±14)	107 (±2)	2 (±1)	98 (±5)	186 (±11)	110 (±1)	28 (±4)	109 (±2)	102 (±1)	130 (±8)	95 (±2)	114 (±56)	12

Where particular low/high recoveries have been observed, these are shaded grey for ease of noting (<35% / >135% - dark grey; <75% / >125% - light grey). Metformin MET; Paracetamol PARA; Trimethoprim TMP; Ciprofloxacin CFX; Carbamazepine-10-11-epoxide CBZ; Propranolol PPL; Carbamazepine CBZ; Clarithromycin CTM; Fluoxetine FLX; Atorvastatin ATV; Ibuprofen IBU; Diclofenac DCF; Estradiol E3; 17β-Estradiol E2; 17α-ethynylestradiol EE2; Estrone E1; Triclosan TCS. Trimethoprim-D9 TMP-D9; Carbamazepine-D10 CBZ-D10; Roxythromycin RTM; Fluoxetine-D5 FLX-D5; Diclofenac-D4 DCF-D4; Estrone-D2 E1-D2; Triclosan-D3 TCS-D3. Methanol MEOH; acetone ACE; ethyl acetate EAC.

Recoveries obtained varied markedly between compounds and SPE conditions used (as may be expected given the physico-chemical diversity of the prioritised compounds). It is evident that data corrected for ILIS recovery (Table 5) provided better results for most target compounds (as compared to absolute recovery data; Table 4). This was most evident for the analytes clarithromycin, fluoxetine, trimethoprim and the estrogens. This indicated that analyte losses occurred throughout the analytical procedure and that ILIS correction helped ensure better quantification (compensating for any losses).

In terms of SPE, higher recovery values were achieved using the Oasis HLB Prime cartridges under the tested conditions. The Oasis HLB Prime provided satisfactory recoveries (>75% and <125%) for more analytes (Table 4 and 5), which may be attributed to the strong hydrophobic interaction between analytes and retention sorbent of HLB prime cartridges (Beltran et al., 2010). For the extremely polar compound metformin, which was previously reported as not recoverable using an SPE procedure, satisfactory recoveries ($102\% \pm 26\%$) were observed in condition 1 (Cahill et al., 2004).

A dependency on SPE pH was observed for certain substances. For instance, the ILIS corrected recovery for propranolol and trimethoprim was enhanced at pH 2, while for carbamazepine-epoxide and metformin it was reduced. Notably, ciprofloxacin was overestimated when using acidified conditions, which may be attributed to pH-induced molecular conformation changes. Ciprofloxacin has a zwitterionic nature and exists in cation, zwitterion, and/or anion species under different pH conditions (see Fig. S3). We postulate that the acidification of the SPE process to pH 2 charged the cationic amine moiety positively, resulting in an increased number of ions entering the MS. The dependency of substances with a zwitterionic nature on pH has also been reported by other authors (Rossmann et al., 2014).

Regarding the optimal SPE conditions, 12 of 17 compounds were recovered at >75% and <125% in tested conditions 1, 2 and 4 based on the ILIS correction (Table 5). Using absolute recoveries (Table 4), condition 2 was found to be most effective (>75% recovery for 10 compounds with HLB Prime). The ILIS corrected values (Table 5) were generally in agreement with the absolute recoveries (Table 4), with the enhancement of recoveries (Table 5) in conditions 1 and 4 suggesting the ILIS correction appropriately ensured successful quantification by compensating for losses of compounds.

391 The ‘optimal’ SPE condition that provided the best recovery for each compound varied
392 due to the variety of physico-chemical properties represented in the priority list. For most
393 target compounds, condition 2 was found the most effective based on the high values of
394 both absolute and ILIS corrected recoveries, therefore was selected for further study.
395 Meanwhile, low recovery was noted for certain substances (metformin, ciprofloxacin and
396 propranolol <35%) in this condition. To reach a compromise, that gives an acceptable
397 recovery for most compounds with the least loss, condition 1, retaining 16 out of 17
398 compounds, with the exception of ciprofloxacin, was also selected for further
399 investigation.

400 Although quantitation with ILIS assured sufficient recoveries, under certain
401 circumstances, the use of ILIS can be a complicated approach for analytes from a diverse
402 range of chemical classes (Gracia-Lor et al., 2011). Quantitation with ILIS needs to be
403 well characterised when it does not ensure an adequate correction. For instance,
404 undesirable enhancement of ILIS recovery was observed for paracetamol while
405 satisfactory absolute values (72-99%) were obtained under tested conditions. Similar
406 inadequate ILIS recovery was found for ibuprofen. This was attributed to the mass loss
407 of its ILIS analogue not coinciding with the analyte under the same conditions so that the
408 ILIS calculation exaggerated the process efficiency, making the ILIS correction
409 unnecessary (Marín et al., 2009; Renew and Huang, 2004). Therefore, the absolute
410 recoveries of paracetamol and ibuprofen have been adopted for evaluation.

411 **2.3 Matrix effect study**

412 The influence of environmental matrix on accurate quantitative LC-MS/MS analysis has
413 been widely discussed (Frigerio et al., 2019; Fu et al., 2018; Huang et al., 2020). Non-
414 target components present in samples can have a significant impact on analyte recovery
415 and ionisation which may deplete or enhance MS signal intensity and thus affect accurate
416 quantification (Irlam et al., 2019; Meerpoel et al., 2018; Tran et al., 2020). The assessment
417 of matrix effect has been conducted in a number of approaches during the development
418 of quantitative analytical method, the most commonly used one may refer to the “absolute”
419 matrix effect, comparing the signal response of a standard present in an extract containing
420 co-eluting components to the response of a standard in a “not contaminated” neat solvent
421 (Matuszewski et al., 2003). Although the presence of this absolute matrix effect (which
422 is often obtained by a comparison of the response of analyte spiked after extraction to the

response in the neat solution) is of some concern, the more important parameter in the evaluation of an analytical method is the demonstration of the absence of a “relative” matrix effect in different sources of environmental water matrices. To validate the overall performance of the analytical method in this study, the effects of water matrices were evaluated by comparing recoveries of analytes in different water matrices (spiked before extraction). The suppression or enhancement of recoveries in **Table 6** demonstrated the overall effects of matrices (undetected coeluting components reacting with primary ions formed in the HPLC–MS/MS interface) and recoveries (competition with matrix components, which can largely be compensated by isotope-labeled internal standards) from different water sources. All values presented were corrected using ILIS, except for paracetamol and ibuprofen, where absolute recoveries are given (due to inadequate ILIS correction as discussed above).

With a number of exceptions, fairly limited effects of matrix were observed for many of these pharmaceuticals and EDCs, which is consistent with previous findings ([Cha et al., 2006](#); [Tong et al., 2009](#); [Tuc Dinh et al., 2011](#)). Some effects were noted for 6 compounds, with >50% recovery suppression for two (atorvastatin and ibuprofen), ~20-40% suppression for three (metformin, paracetamol and clarithromycin) and <20% enhancement for trimethoprim. This was likely due to ion suppression in the MS ESI source due to matrix components ([Gómez et al., 2006](#); [Kasprzyk-Hordern et al., 2008](#)). The lack of ILIS correction for paracetamol and ibuprofen likely made these effects more obvious and meant effective correction could not be achieved. For atorvastatin, its high Log K_{ow} (6.36) suggests the compound would tend to bind with organic matter present in water – and the SPE process presumably failed to overcome this. For several analytes (e.g., E3, paracetamol, trimethoprim, clarithromycin), a filtered river water matrix resulted in lower recovery versus unfiltered, indicating no filtration is beneficial to remain pharmaceutical compounds when recovering them from environmental water matrices. This may be attributed to the pharmaceutical analytes sorbed onto suspended particular matter present in the river samples, which was then removed during membrane filtration, causing the concentrations of freely dissolved analytes to be lower for further detection. The co-extracting components in river water matrix may also mask the analyte peaks by raising the chromatogram baseline, leading to underestimated integrated peak areas. Meanwhile, the co-extracting matrix may reduce ionisation efficiency of the analytes by taking up some of the limited number of excess charged sites on the surfaces of

456 electrosprayed droplets (Gómez et al., 2006). This is consistent with other studies and may
457 suggest that analysing samples without filtration may sometimes be more appropriate
458 (depending on the analytes concerned and aims of the study) (Berset and Ochsenbein,
459 2012; Tran et al., 2013). For filtered river samples, methanol elution provided better
460 recoveries for most target compounds in this study. In terms of limits of quantification
461 (LOQs) calculated when processing 1 L of water - these were in the range of $0.07 \text{ ng}\cdot\text{L}^{-1}$
462 to $9.07 \text{ ng}\cdot\text{L}^{-1}$ (as shown in **Table 6**). For 14 out of 17 compounds (excluding ibuprofen,
463 ciprofloxacin and E3), method LOQs were $0.07 \text{ ng}\cdot\text{L}^{-1}$ to $1.88 \text{ ng}\cdot\text{L}^{-1}$, which is somewhat
464 lower than those previously reported in other studies (Choi et al., 2007; Ding et al., 2009;
465 Tuc Dinh et al., 2011).

Table 6. Recoveries of prioritised pharmaceuticals and EDCs in different water matrices (using ILIS correction, except for paracetamol and ibuprofen)

Recoveries % and (±%RSD)		Analytes detected in -ve mode							Analytes detected in +ve mode										No. >75% and <125%
		IBU	DCF	E3	E2	EE2	E1	TCS	MET	PARA	CFX	TMP	CBZE	PPL	CBZ	CTM	FLX	ATV	
Applied ILIS			DCF-D4	E1-D2			TCS-D3	TMP-D9		TMP-D9			CBZ-D10			RTM	FLX-D5		
MEOH	Milli-Q	71 (±10)	92 (±3)	112 (±8)	103 (±6)	96 (±5)	97 (±3)	92 (±4)	102 (±26)	93 (±2)	4 (±1)	117 (±3)	95 (±1)	63 (±0)	88 (±1)	126 (±4)	85 (±1)	113 (±5)	13
	Tap Water	32 (±3)	100 (±1)	129 (±9)	116 (±5)	115 (±21)	95 (±1)	96 (±0)	47 (±11)	51 (±5)	26 (±10)	137 (±2)	112 (±3)	60 (±4)	101 (±2)	105 (±9)	100 (±3)	43 (±0)	9
	River water Unfiltered	5 (±4)	99 (±2)	112 (±14)	98 (±10)	102 (±15)	96 (±3)	109 (±1)	44 (±2)	62 (±3)	6 (±5)	131 (±8)	110 (±1)	65 (±6)	97 (±3)	108 (±3)	93 (±4)	14 (±5)	10
	River water Filtered	14 (±5)	100 (±6)	81 (±2)	103 (±24)	104 (±20)	96 (±0)	107 (±2)	60 (±1)	55 (±14)	10 (±3)	124 (±1)	111 (±1)	73 (±1)	97 (±1)	89 (±4)	95 (±1)	55 (±4)	11
ACE:EAC	Milli-Q	90 (±6)	94 (±1)	96 (±6)	99 (±4)	93 (±3)	96 (±3)	99 (±3)	31 (±7)	99 (±2)	2 (±1)	113 (±2)	99 (±1)	29 (±7)	90 (±0)	135 (±16)	82 (±5)	123 (±7)	13
	Tap Water	40 (±2)	97 (±1)	96 (±4)	99 (±2)	92 (±12)	90 (±4)	105 (±4)	2 (±1)	67 (±5)	1 (±0)	130 (±7)	101 (±2)	21 (±5)	96 (±2)	103 (±5)	94 (±5)	6 (±3)	10
	River water Unfiltered	13 (±4)	97 (±1)	96 (±23)	98 (±6)	93 (±4)	98 (±3)	106 (±2)	3 (±0)	57 (±9)	1 (±2)	121 (±8)	107 (±3)	33 (±9)	88 (±0)	107 (±5)	97 (±2)	4 (±2)	11
	River water Filtered	13 (±1)	105 (±2)	81 (±6)	97 (±1)	98 (±5)	95 (±1)	100 (±4)	3 (±1)	56 (±6)	1 (±0)	119 (±32)	112 (±8)	39 (±11)	92 (±4)	104 (±2)	103 (±6)	57 (±0)	11
Method LOQ (ng·L ⁻¹)		9.07	0.78	4.48	1.31	1.88	0.66	1.61	0.27	0.69	4.46	0.08	0.09	0.39	0.11	0.07	0.10	0.70	

Where clearest reductions in recovery are evident (i.e., matrix effects most likely), these have been shaded grey for ease of noting (>50% dark grey; 20-40% light grey; reduction owing to suspended particulate matter- medium grey). .Metformin MET; Paracetamol PARA; Trimethoprim TMP; Ciprofloxacin CFX; Carbamazepine-10-11-epoxide CBZ; Propranolol PPL; Carbamazepine CBZ; Clarithromycin CTM; Fluoxetine FLX; Atorvastatin ATV; Ibuprofen IBU; Diclofenac DCF; Estriol E3; 17β-Estradiol E2; 17α-ethynylestradiol EE2; Estrone E1; Triclosan TCS. Trimethoprim-D9 TMP-D9; Carbamazepine-D10 CBZ-D10; Roxythromycin RTM; Fluoxetine-D5 FLX-D5; Diclofenac-D4 DCF-D4; Estrone-D2 E1-D2; Triclosan-D3 TCS-D3. Methanol MEOH; acetone ACE; ethyl acetate EAC.

466 2.4 Analysis of real water samples

467 To validate the applicability of this method, it was applied to identify and quantify 8
 468 priority pharmaceuticals and EDCs in various real water samples (to fit in the target of
 469 the hospital monitoring project – possible detected analytes based on local description
 470 data). Given the matrix effects observed in testing, an additional ILIS (paracetamol-D4)
 471 was applied (relevant recovery data was provided in Supporting information **Table S3**).
 472 Monitoring results are presented in **Table 7**.

473 **Table 7.** Summary of the field monitoring results obtained for 8 target compounds (ng·L⁻¹) in
 474 real water samples. Samples collected from a combined rural hospital discharge (Wick General,
 475 Scotland), and, the influent and effluent from Wick municipal WWTP

Compound	Hospital discharge (n = 20)		Wastewater influent (n = 20)		Wastewater effluent (n = 20)	
	Detection frequency (%)	Mean (range)	Detection frequency (%)	Mean (range)	Detection frequency (%)	Mean (range)
Paracetamol	100	33,267 (7,959-105,910)	100	67,483 (5,849-105,780)	100	8,567 (516-36,201)
Trimethoprim	85	818 (<LOD-9,111)	100	621 (155-2,170)	84	440 (<LOD-634)
Carbamazepine	100	13 (3-47)	100	306 (40-684)	100	459 (212-709)
Clarithromycin	45	1,271 (<LOD-7,940)	57	246 (<LOD-830)	100	371 (60-836)
Fluoxetine	32	16 (<LOD-37)	26	19 (<LOD-46)	15	16 (<LOD-29)
Ibuprofen	45	139 (<LOD-675)	100	471 (5-6,018)	73	73 (<LOD-178)
Diclofenac	75	77 (<LOD-593)	63	196 (<LOD-392)	36	102 (<LOD-250)
EE2	0	<LOD	0	<LOD	0	<LOD

476 Beyond those sites shown in **Table 7**, no target pharmaceuticals were detected (>LOQ)
 477 in the surface source water or the treated hospital drinking water supply tested. Likewise,
 478 EE2 was never found (< LOQ = 1.88 ng·L⁻¹), the method LOD standard of which has
 479 been updated to 0.035 ng·L⁻¹ based on the Commission Implementing Decision
 480 (European Commission, 2018), suggesting the challenge and necessity of improving the
 481 analytical methodology to monitor such compounds at lower concentrations. In the
 482 hospital discharge, all the targeted pharmaceuticals were detected except EE2, with
 483 paracetamol and carbamazepine detected in every sample. The highest concentrations
 484 were recorded for paracetamol, with a maximum of 105,910 ng·L⁻¹, followed by
 485 trimethoprim (9,111 ng·L⁻¹) and clarithromycin (7,940 ng·L⁻¹). Regarding the WWTP
 486 wastewater influent tested, the highest levels were noted for paracetamol (105,780 ng·L⁻¹)
 487 and ibuprofen (6,018 ng·L⁻¹). The increased mean detection level of paracetamol
 488 (33267 ng·L⁻¹ to 67483 ng·L⁻¹) and ibuprofen (139 ng·L⁻¹ to 471 ng·L⁻¹) between the

hospital discharge and wastewater influent indicated the possible presence of other inputting sources of such pharmaceuticals besides the hospital discharge. Lower levels of trimethoprim (818 ng·L⁻¹ to 621 ng·L⁻¹) and clarithromycin (1271 ng·L⁻¹ to 246 ng·L⁻¹) in WWTP influent versus the hospital discharge may be attributed to the degradation and/or dilution in the aquatic environment between those two sites (Gracia-Lor et al., 2011). Higher levels of carbamazepine and ibuprofen may reflect greater (human) intakes in the community versus the hospital. In terms of the final WWTP effluent, all the previously detected pharmaceuticals remained detectable – albeit at reduced levels in some cases. Five of the pharmaceuticals monitored were at lower mean levels in discharge versus influent – but, two (carbamazepine, clarithromycin) were more elevated in discharge water. These results reinforce the need to apply multiclass pharmaceutical monitoring methods in order to gain a better understanding of the fate/behaviour of these compounds at the catchment scale. Likewise, they highlight the ongoing need to create WWTP processes that can efficiently eliminate these bioactive pollutants of concern.

Compared to levels reported in other European countries for these target compounds (Gros et al., 2010; Gros et al., 2007; López-Serna et al., 2011), the surface water data collected here demonstrated how relatively ‘pristine’ source water can be in the Scottish Highlands (in a remote inland lake, currently entirely ‘free’ of these contaminants). However, the WWTP concentrations seen here (both influent and effluent) were highly comparable with data from Germany, Belgium and the US (Cahill et al., 2004; Gurke et al., 2015a; Rossmann et al., 2014; Vergeynst et al., 2015). This clearly highlights the impact that pharmaceutical consumption is and can have – even in remote and otherwise pristine hydrological systems.

3. Conclusion

A sensitive analytical methodology for the simultaneous determination of up to 17 priority pharmaceuticals and EDCs was developed and validated using an optimised SPE protocol and HPLC-ESI-MS/MS detection. A risk-based approach was applied to identify compounds that may pose the greatest environmental concern. The diversity of analytes selected meant that some compromises were needed when applying this analysis (i.e., accepting reduced recovery for certain compounds). The optimal SPE protocol used Oasis HLB Prime cartridges with no pH adjustment and elution with methanol. The use of ILIS improved the reliability of the entire process and helped evaluation of matrix effects.

521 Application of the method to ‘real’ environmental samples from a rural catchment in
522 Scotland, illustrated the occurrence of pharmaceuticals in various wastewater matrices.
523 The highest concentrations found were for paracetamol, with a mean level of 67,483 ng·L⁻¹
524 ¹ in municipal WWTP influent. The successful application of this method to real water
525 matrices validated its applicability within routine monitoring studies regarding these
526 priority pharmaceutical and EDC contaminants.

527 **Appendix A. Supplementary material**

528 Supplementary data associated with this article is present in the Supporting
529 Information.

530 **Acknowledgements**

531 This work has been undertaken as part of The Hydro Nation Scholars Programme
532 and supported by The Centre of Expertise for Waters (CREW) on behalf of the Scottish
533 Government. The authors would like to thank the support from the Scottish Government’s
534 Rural and Environment Science and Analytical Service Division (RESAS).

535

536

537

538 **List of tables**

539

540 **List of figures**

541

References

- Almeida, Â., Silva, M.G., Soares, A.M., Freitas, R., 2020. Concentrations levels and effects of 17alpha-Ethinylestradiol in freshwater and marine waters and bivalves: A review. *Environ. Res.* 109316
- Ashton, D., Hilton, M. & Thomas, K.V., 2004. Investigating the environmental transport of human pharmaceuticals to streams in the United Kingdom. *Sci. Total Environ.* 333 (1–3), 167-184
- Beltran, A., Borrull, F., Marcé, R.M., Cormack, P.A.G., 2010. Molecularly-imprinted polymers: useful sorbents for selective extractions. *Trends Analyt Chem.* 11, 1363-1375
- Berset, J.-., Ochsenbein, N., 2012. Stability considerations of aspartame in the direct analysis of artificial sweeteners in water samples using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). *Chemosphere.* 5, 563-569
- Booth, A., Aga, D.S., Wester, A.L., 2020. Retrospective analysis of the global antibiotic residues that exceed the predicted no effect concentration for antimicrobial resistance in various environmental matrices. *Environ. Int.* 105796
- Boxall, A.B., Rudd, M.A., Brooks, B.W., Caldwell, D.J., Choi, K., Hickmann, S., et al., 2012. Pharmaceuticals and personal care products in the environment: what are the big questions?. *Environ. Health Perspect.* 9, 1221
- Botero-Coy, A.M., Martínez-Pachón, D., Boix, C., Rincón, R.J., Castillo, N., Arias-Marín, L., et al., 2018. An investigation into the occurrence and removal of pharmaceuticals in Colombian wastewater. *Sci. Total Environ.* 842-853
- Brack, W., Dulio, V., Ågerstrand, M., Allan, I., Altenburger, R., Brinkmann, M., et al., 2017. Towards the review of the European Union Water Framework Directive: Recommendations for more efficient assessment and management of chemical contamination in European surface water resources. *Sci. Total Environ.* 720-737
- Brodin, T., Fick, J., Jonsson, M., Klaminder, J., 2013. Dilute concentrations of a psychiatric drug alter behavior of fish from natural populations. *Science.* 6121, 814-815
- Buchberger, W.W., 2011. Current approaches to trace analysis of pharmaceuticals and personal care products in the environment. *J. Chromatogr. A.* 4, 603-618

- Burkhardt-Holm, P., 2010. Endocrine disruptors and water quality: A state-of-the-art review. *Int. J. Water Resour. Dev.* 3, 477-493
- Cahill, J.D., Furlong, E.T., Burkhardt, M.R., Kolpin, D., Anderson, L.G., 2004. Determination of pharmaceutical compounds in surface- and ground-water samples by solid-phase extraction and high-performance liquid chromatography–electrospray ionization mass spectrometry. *J. Chromatogr. A.* 1, 171-180
- Calisto, V., Esteves, V.I., 2009. Psychiatric pharmaceuticals in the environment. *Chemosphere.* 10, 1257-1274
- Carusso, S., Juárez, A., Moretton, J., Magdaleno, A., 2018. Effects of three veterinary antibiotics and their binary mixtures on two green alga species. *Chemosphere.* 821-827
- Ccancapa, A., Masiá, A., Navarro-Ortega, A., Picó, Y., Barceló, D., 2016. Pesticides in the Ebro River basin: occurrence and risk assessment. *Environ. Pollut.* 414-424
- Cha, J.M., Yang, S., Carlson, K.H., 2006. Trace determination of β -lactam antibiotics in surface water and urban wastewater using liquid chromatography combined with electrospray tandem mass spectrometry. *J. Chromatogr. A.* 1, 46-57
- Charuaud, L., Jardé, E., Jaffrézic, A., Thomas, M., Le Bot, B., 2019. Veterinary pharmaceutical residues from natural water to tap water: Sales, occurrence and fate. *J. Hazard. Mater.* 169-186
- Choi, K., Kim, S., Kim, C., Kim, S., 2007. Determination of antibiotic compounds in water by on-line SPE-LC/MSD. *Chemosphere.* 6, 977-984
- Colman, J.R., Baldwin, D., Johnson, L.L., Scholz, N.L., 2009. Effects of the synthetic estrogen, 17 α -ethinylestradiol, on aggression and courtship behavior in male zebrafish (*Danio rerio*). *Aquat. Toxicol.* 4, 346-354
- Czarny, K., Szczukocki, D., Krawczyk, B., Skrzypek, S., Zieliński, M., Gadzała-Kopciuch, R., 2019. Toxic effects of single animal hormones and their mixtures on the growth of *Chlorella vulgaris* and *Scenedesmus armatus*. *Chemosphere.* 93-102
- De Liguoro, M., Di Leva, V., Dalla Bona, M., Merlanti, R., Caporale, G., Radaelli, G., 2012. Sublethal effects of trimethoprim on four freshwater organisms. *Ecotoxicol. Environ. Saf.* 114-121
- De Souza, Sandra Maria Lopes, de Vasconcelos, E.C., Dziedzic, M., de Oliveira, Cíntia Mara Ribas, 2009. Environmental risk assessment of antibiotics: an intensive care unit analysis. *Chemosphere.* 7, 962-967

- Ding, J., Ren, N., Chen, L., Ding, L., 2009. On-line coupling of solid-phase extraction to liquid chromatography–tandem mass spectrometry for the determination of macrolide antibiotics in environmental water. *Analytica Chimica Acta*. 2, 215-221
- Dionísio, R., Daniel, D., de Alkimin, G.D., Nunes, B., 2020. Multi-parametric analysis of ciprofloxacin toxicity at ecologically relevant levels: Short-and long-term effects on *Daphnia magna*. *Environ. Toxicol. Pharmacol.* 103295
- European commission, 2018, Commission Implementing Decision (EU) 2018/840 of 5 June 2018 establishing a watch list of substances for Union-wide monitoring in the field of water policy pursuant to Directive 2008/105/EC of the European Parliament and of the Council and repealing Commission Implementing Decision (EU) 2015/495, OJ L141, 7.6.2018, pp.9-12
- European Commission, 2015, European Commission Implementation Decision 2015/495/EC establishing a watch list of substances for Union-wide monitoring in the field of water policy pursuant to Directive 2008/105/EC of the European Parliament and of the Council, Off. J. Eur. Union, 58 (2015), pp. 40-42
- European Commission. 2008, Directive 2008/105/EC of the European Parliament and of the Council on environmental quality standards in the field of water policy, amending and subsequently repealing Council Directives 82/176/EEC, 83/513/EEC, 84/156/EEC, 84/491/EEC, 86/280/EEC and amending Directive 2000/60/EC of the European Parliament and of the Council, Off. J. Eur. Union, 51 (2008), pp. 84-97
- Fekadu, S., Alemayehu, E., Dewil, R., Van der Bruggen, B., 2019. Pharmaceuticals in freshwater aquatic environments: A comparison of the African and European challenge. *Sci. Total Environ.* 324-337
- Ferrer, I., Zweigenbaum, J.A., Thurman, E.M., 2010. Analysis of 70 Environmental Protection Agency priority pharmaceuticals in water by EPA Method 1694. *Journal of Chromatography A*. 36, 5674-5686
- Foster, H.R., Burton, G.A., Basu, N., Werner, E.E., 2010. Chronic exposure to fluoxetine (Prozac) causes developmental delays in *Rana pipiens* larvae. *Environ. Toxicol. Chem.* 12, 2845-2850
- Frigerio, G., Mercadante, R., Polledri, E., Missineo, P., Campo, L., Fustinoni, S., 2019. An LC-MS/MS method to profile urinary mercapturic acids, metabolites of electrophilic intermediates of occupational and environmental toxicants. *J. Chromatogr. A*. 66-76

- Fu, L., Lu, X., Tan, J., Wang, L., Chen, J., 2018. Multiresidue determination and potential risks of emerging pesticides in aquatic products from Northeast China by LC-MS/MS. *J. Environ. Sci.* 116-125
- Fursdon, J.B., Martin, J.M., Bertram, M.G., Lehtonen, T.K., Wong, B.B., 2019. The pharmaceutical pollutant fluoxetine alters reproductive behaviour in a fish independent of predation risk. *Sci. Total Environ.* 642-652
- Golet, E.M., Alder, A.C., Hartmann, A., Ternes, T.A., Giger, W., 2001. Trace determination of fluoroquinolone antibacterial agents in urban wastewater by solid-phase extraction and liquid chromatography with fluorescence detection. *Anal. Chem.* 15, 3632-3638
- Gómez, M.J., Petrovic, M., Fernández-Alba, A.R., Barceló, D., 2006. Determination of pharmaceuticals of various therapeutic classes by solid-phase extraction and liquid chromatography-tandem mass spectrometry analysis in hospital effluent wastewaters. *J. Chromatogr. A.* 2, 224-233
- Gorga, M., Petrovic, M., Barceló, D., 2013. Multi-residue analytical method for the determination of endocrine disruptors and related compounds in river and waste water using dual column liquid chromatography switching system coupled to mass spectrometry. *J. Chromatogr. A.* 57-66
- Gracia-Lor, E., Sancho, J.V., Hernández, F., 2011. Multi-class determination of around 50 pharmaceuticals, including 26 antibiotics, in environmental and wastewater samples by ultra-high performance liquid chromatography–tandem mass spectrometry. *J. Chromatogr. A.* 16, 2264-2275
- Gros, M., Petrović, M., Ginebreda, A., Barceló, D., 2010. Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. *Environ. Int.* 1, 15-26
- Gros, M., Petrovic, M., Barceló, D., 2007. Wastewater treatment plants as a pathway for aquatic contamination by pharmaceuticals in the ebro river basin (northeast Spain). *Environ. Toxicol. Chem.* 8, 1553-1562
- Gros, M., Petrovic, M., Ginebreda, A., Barceló, D., 2010. Removal of pharmaceuticals during wastewater treatment and environmental risk assessment using hazard indexes. *Environ. Int.* 1, 15-26
- Gurke, R., Rößler, M., Marx, C., Diamond, S., Schubert, S., Oertel, R., Fauler, J., 2015a. Occurrence and removal of frequently prescribed pharmaceuticals and

- corresponding metabolites in wastewater of a sewage treatment plant. *Sci. Total Environ.* 762-770
- Gurke, R., Rossmann, J., Schubert, S., Sandmann, T., Rößler, M., Oertel, R., Fauler, J., 2015b. Development of a SPE-HPLC–MS/MS method for the determination of most prescribed pharmaceuticals and related metabolites in urban sewage samples. *J. Chromatogr. B.* 23-30
- Hellström, G., Klaminder, J., Finn, F., Persson, L., Alanärä, A., Jonsson, M., Fick, J., Brodin, T., 2016. GABAergic anxiolytic drug in water increases migration behaviour in salmon. *Nature communications.* 13460
- Hernando-Amado, S., Coque, T.M., Baquero, F., Martínez, J.L., 2019. Defining and combating antibiotic resistance from One Health and Global Health perspectives. *Nature microbiology.* 9, 1432-1442
- Hong, Y., Lee, I., Lee, W., Kim, H., 2019. Mass-balance-model-based evaluation of sewage treatment plant contribution to residual pharmaceuticals in environmental waters. *Chemosphere.* 378-387
- Huang, S., Zhang, H., Ng, T.C.A., Xu, B., Shi, X., Ng, H.Y., 2020. Analysis of N-Acetyl-L-homoserine lactones (AHLs) in wastewater treatment systems using SPE-LLE with LC-MS/MS. *Water Res.* 115756
- Huff, M., da Silveira, W.A., Carnevali, O., Renaud, L., Hardiman, G., 2018. Systems analysis of the liver transcriptome in adult male zebrafish exposed to the plasticizer (2-ethylhexyl) phthalate (DEHP). *Scientific reports.* 1, 1-17
- Information Services Division (ISD), 2016. Prescribing And Medicines: Prescription Cost Analysis.
- Irlam, R.C., Parkin, M.C., Brabazon, D.P., Beardah, M.S., O'Donnell, M., Barron, L.P., 2019. Improved determination of femtogram-level organic explosives in multiple matrices using dual-sorbent solid phase extraction and liquid chromatography-high resolution accurate mass spectrometry. *Talanta.* 65-76
- Jackson, L.M., Felgenhauer, B.E., Klerks, P.L., 2019. Feminization, altered gonadal development, and liver damage in least killifish (*Heterandria formosa*) exposed to sublethal concentrations of 17 β -ethinylestradiol. *Ecotoxicol. Environ. Saf.* 331-337
- Johansson, S.R., 1998. The Greatest Benefit to Mankind: A Medical History of Humanity from Antiquity to the Present. *Population and Development Review.* 3, 624-624
- Kallenborn, R., Brorström-Lundén, E., Reiersen, L., Wilson, S., 2018. Pharmaceuticals and personal care products (PPCPs) in Arctic environments: indicator contaminants

- for assessing local and remote anthropogenic sources in a pristine ecosystem in change. *Environ. Sci. Pollut. Res.* 33, 33001-33013
- Kasprzyk-Hordern, B., Dinsdale, R.M., Guwy, A.J., 2008. The occurrence of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs in surface water in South Wales, UK. *Water Res.* 13, 3498-3518
- Kasprzyk-Hordern, B., Dinsdale, R.M., Guwy, A.J., 2009. The removal of pharmaceuticals, personal care products, endocrine disruptors and illicit drugs during wastewater treatment and its impact on the quality of receiving waters. *Water Res.* 2, 363-380
- Kolpin, D.W., Furlong, E.T., Meyer, M.T., Thurman, E.M., Zaugg, S.D., Barber, L.B., Buxton, H.T., 2002. Pharmaceuticals, hormones, and other organic wastewater contaminants in US streams, 1999-2000: A national reconnaissance. *Environ. Sci. Technol.* 6, 1202-1211
- Kötke, D., Gandrass, J., Xie, Z., Ebinghaus, R., 2019. Prioritised pharmaceuticals in German estuaries and coastal waters: Occurrence and environmental risk assessment. *Environ. Pollut.* 113161
- Kumar, M., Ram, B., Honda, R., Poopipattana, C., Canh, V.D., Chaminda, T., Furumai, H., 2019. Concurrence of antibiotic resistant bacteria (ARB), viruses, pharmaceuticals and personal care products (PPCPs) in ambient waters of Guwahati, India: Urban vulnerability and resilience perspective. *Sci. Total Environ.*, 133640
- Li, Y., Zhang, L., Ding, J., Liu, X., 2020. Prioritization of pharmaceuticals in water environment in China based on environmental criteria and risk analysis of top-priority pharmaceuticals. *J. Environ. Manage.* 109732
- Lindberg, R.H., Olofsson, U., Rendahl, P., Johansson, M.I., Tysklind, M., Andersson, B.A., 2006. Behavior of fluoroquinolones and trimethoprim during mechanical, chemical, and active sludge treatment of sewage water and digestion of sludge. *Environ. Sci. Technol.* 3, 1042-1048
- Löffler, D., Ternes, T.A., 2003. Determination of acidic pharmaceuticals, antibiotics and ivermectin in river sediment using liquid chromatography–tandem mass spectrometry. *J. Chromatogr. A.* 1–2, 133-144
- López-Serna, R., Petrović, M., Barceló, D., 2011. Development of a fast instrumental method for the analysis of pharmaceuticals in environmental and wastewaters based on ultra high performance liquid chromatography (UHPLC)–tandem mass spectrometry (MS/MS). *Chemosphere.* 8, 1390-1399

- Mansour, F., Al-Hindi, M., Saad, W., Salam, D., 2016. Environmental risk analysis and prioritization of pharmaceuticals in a developing world context. *Sci. Total Environ.* 31-43
- Marín, J.M., Gracia-Lor, E., Sancho, J.V., López, F.J., Hernández, F., 2009. Application of ultra-high-pressure liquid chromatography-tandem mass spectrometry to the determination of multi-class pesticides in environmental and wastewater samples. Study of matrix effects. *J. Chromatogr. A.* 9, 1410-1420
- Matuszewski, B., Constanzer, M., Chavez-Eng, C., 2003. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. *Anal. Chem.* 13, 3019-3030
- Meerpoel, C., Vidal, A., di Mavungu, J.D., Huybrechts, B., Tangni, E.K., Devreese, M., Croubels, S., De Saeger, S., 2018. Development and validation of an LC–MS/MS method for the simultaneous determination of citrinin and ochratoxin a in a variety of feed and foodstuffs. *J. Chromatogr. A.* 100-109
- Miao, X., Metcalfe, C.D., 2003. Determination of carbamazepine and its metabolites in aqueous samples using liquid chromatography-electrospray tandem mass spectrometry. *Anal. Chem.* 15, 3731-3738
- Miarov, O., Tal, A., Avisar, D., 2020. A critical evaluation of comparative regulatory strategies for monitoring pharmaceuticals in recycled wastewater. *J. Environ. Manage.* 109794
- Nijssingh, N., Munthe, C., Larsson, D.J., 2019. Correction to: Managing pollution from antibiotics manufacturing: charting actors, incentives and disincentives. *Environ. Health.* 1, 108
- Nunes, B., Antunes, S.C., Santos, J., Martins, L., Castro, B.B., 2014. Toxic potential of paracetamol to freshwater organisms: A headache to environmental regulators?. *Ecotoxicol. Environ. Saf.* 178-185
- Östman, M., Fick, J., Tysklind, M., 2018. Detailed mass flows and removal efficiencies for biocides and antibiotics in Swedish sewage treatment plants. *Sci. Total Environ.* 327-336
- Peng, Y., Gautam, L., Hall, S.W., 2019. The detection of drugs of abuse and pharmaceuticals in drinking water using solid-phase extraction and liquid chromatography-mass spectrometry. *Chemosphere.* 438-447
- Pereira, A.M.P.T., Silva, L.J.G., Lino, C.M., Meisel, L.M., Pena, A., 2016. Assessing environmental risk of pharmaceuticals in Portugal: An approach for the selection of

- the Portuguese monitoring stations in line with Directive 2013/39/EU. *Chemosphere*. 2507-2515
- Petrie, B., Barden, R., Kasprzyk-Hordern, B., 2015. A review on emerging contaminants in wastewaters and the environment: Current knowledge, understudied areas and recommendations for future monitoring. *Water Res.* 3-27
- Petrović, M., Hernando, M.D., Díaz-Cruz, M.S., Barceló, D., 2005. Liquid chromatography–tandem mass spectrometry for the analysis of pharmaceutical residues in environmental samples: a review. *J. Chromatogr. A*. 1-2, 1-14
- Qin, G., Zhang, Y., Zhang, B., Zhang, Y., Liu, Y., Lin, Q., 2020. Environmental estrogens and progestins disturb testis and brood pouch development with modifying transcriptomes in male-pregnancy lined seahorse *Hippocampus erectus*. *Sci. Total Environ.* 136840
- Radjenović, J., Petrović, M. & Barceló, D., 2009. Fate and distribution of pharmaceuticals in wastewater and sewage sludge of the conventional activated sludge (CAS) and advanced membrane bioreactor (MBR) treatment. *Water Res.* 43 (3), 831-841
- Renew, J.E., Huang, C.-., 2004. Simultaneous determination of fluoroquinolone, sulfonamide, and trimethoprim antibiotics in wastewater using tandem solid phase extraction and liquid chromatography-electrospray mass spectrometry. *J. Chromatogr. A*. 1-2, 113-121
- Roberts, P.H., Thomas, K.V., 2006. The occurrence of selected pharmaceuticals in wastewater effluent and surface waters of the lower Tyne catchment. *Sci. Total Environ.* 1, 143-153
- Roos, V., Gunnarsson, L., Fick, J., Larsson, D., Rudén, C., 2012. Prioritising pharmaceuticals for environmental risk assessment: towards adequate and feasible first-tier selection. *Sci. Total Environ.* 102-110
- Rossmann, J., Schubert, S., Gurke, R., Oertel, R., Kirch, W., 2014. Simultaneous determination of most prescribed antibiotics in multiple urban wastewater by SPE-LC–MS/MS. *J. Chromatogr. B*. 162-170
- Roy, R.Y., Peterson, D.R., Kitamura, S., Segner, H., Seemann, F., Au, D.W., 2018. Sex-specific immunomodulatory action of the environmental estrogen 17 β -ethynylestradiol alongside with reproductive impairment in fish. *Aquat. Toxicol.* 95-106

- Ruan, Y., Wu, R., Lam, J.C., Zhang, K., Lam, P.K., 2019. Seasonal occurrence and fate of chiral pharmaceuticals in different sewage treatment systems in Hong Kong: Mass balance, enantiomeric profiling, and risk assessment. *Water Res.* 607-616
- Scheurer, M., Brauch, H.-., Lange, F.T., 2009. Analysis and occurrence of seven artificial sweeteners in German waste water and surface water and in soil aquifer treatment (SAT). *Anal. Bioanal. Chem.* 6, 1585-1594
- Tong, L., Li, P., Wang, Y., Zhu, K., 2009. Analysis of veterinary antibiotic residues in swine wastewater and environmental water samples using optimized SPE-LC/MS/MS. *Chemosphere.* 8, 1090-1097
- Tran, N.H., Li, Y., Reinhard, M., He, Y., Gin, K.Y., 2020. A sensitive and accurate method for simultaneous analysis of algal toxins in freshwater using UPLC-MS/MS and 15N-microcystins as isotopically labelled internal standards. *Sci. Total Environ.* 139-727
- Tran, N.H., Hu, J., Ong, S.L., 2013. Simultaneous determination of PPCPs, EDCs, and artificial sweeteners in environmental water samples using a single-step SPE coupled with HPLC-MS/MS and isotope dilution. *Talanta*, 82-92
- Ujhegyi, N., Bókony, V., 2020. Skin coloration as a possible non-invasive marker for skewed sex ratios and gonadal abnormalities in immature common toads (*Bufo bufo*). *Ecol. Ind.*, 106175
- UKWIR, 2014, Risk Based Prioritisation of Pharmaceuticals UKWIR Report, 14/WW/17/16 (August 2014), (ISBN: 1840577355)
- UKWIR, 2019, Chemical Investigation Programme (CIP). National Report - Risk assessment of CIP data with respect to implications for drinking water sources
- Van De Steene, J.C., Mortier, K.A., Lambert, W.E., 2006. Tackling matrix effects during development of a liquid chromatographic-electrospray ionisation tandem mass spectrometric analysis of nine basic pharmaceuticals in aqueous environmental samples. *J. Chromatogr. A.* 1, 71-81
- Vazquez-Roig, P., Segarra, R., Blasco, C., Andreu, V., Picó, Y., 2010. Determination of pharmaceuticals in soils and sediments by pressurized liquid extraction and liquid chromatography tandem mass spectrometry. *J. Chromatogr. A.* 16, 2471-2483
- Vergeynst, L., Haeck, A., De Wispelaere, P., Van Langenhove, H., Demeestere, K., 2015. Multi-residue analysis of pharmaceuticals in wastewater by liquid chromatography-magnetic sector mass spectrometry: Method quality assessment and application in a Belgian case study. *Chemosphere.* S2-S8

- Verlicchi, P., Al Aukidy, M., Galletti, A., Petrovic, M., Barceló, D., 2012. Hospital effluent: investigation of the concentrations and distribution of pharmaceuticals and environmental risk assessment. *Sci. Total Environ.* 109-118
- Voulvoulis, N., Arpon, K.D., Giakoumis, T., 2017. The EU Water Framework Directive: From great expectations to problems with implementation. *Sci. Total Environ.* 358-366
- Yu, H., Caldwell, D.J., Suri, R.P., 2019. In vitro estrogenic activity of representative endocrine disrupting chemicals mixtures at environmentally relevant concentrations. *Chemosphere.* 396-403
- Yuan, L., 2019. The removal of pharmaceuticals and EDCs from water by low-cost sorbents, PhD thesis, University of Aberdeen
- Yuan, X., Qiang, Z., Ben, W., Zhu, B., Liu, J., 2014. Rapid detection of multiple class pharmaceuticals in both municipal wastewater and sludge with ultra high performance liquid chromatography tandem mass spectrometry. *J. Environ. Sci.* 9, 1949-1959
- Zhang, Z., Wang, J., Pan, Z., Zhang, Y., Zhang, X., Tian, H., et al., 2019. Distribution of vitellogenin in Japanese flounder (*Paralichthys olivaceus*) for biomarker analysis of marine environmental estrogens. *Aquat. Toxicol.* 105-321
- Zhou, X., Li, Y., Li, H., Yang, Z., Zuo, C., 2019. Responses in the crucian carp (*Carassius auratus*) exposed to environmentally relevant concentration of 17 β -Ethinylestradiol based on metabolomics. *Ecotoxicol. Environ. Saf.* 109-501.